These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1812362)

  • 21. Soluble paramagnetic chelates and stabilized colloidal particle solutions of iron oxides as contrast agents for magnetic resonance imaging.
    Tombach B; Reimer P
    Curr Med Chem; 2005; 12(23):2795-804. PubMed ID: 16305473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted relaxation enhancement agents for MRI.
    Lauffer RB
    Magn Reson Med; 1991 Dec; 22(2):339-42; discussion 343-6. PubMed ID: 1812368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biocompatible and Biodegradable Fe
    Lee MY; Choi D; Jang MS; Lee JH
    Bioconjug Chem; 2018 Jul; 29(7):2426-2435. PubMed ID: 29856914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular imaging of activated platelets via antibody-targeted ultra-small iron oxide nanoparticles displaying unique dual MRI contrast.
    Ta HT; Li Z; Hagemeyer CE; Cowin G; Zhang S; Palasubramaniam J; Alt K; Wang X; Peter K; Whittaker AK
    Biomaterials; 2017 Jul; 134():31-42. PubMed ID: 28453956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendronized iron oxide nanoparticles as contrast agents for MRI.
    Basly B; Felder-Flesch D; Perriat P; Billotey C; Taleb J; Pourroy G; Begin-Colin S
    Chem Commun (Camb); 2010 Feb; 46(6):985-7. PubMed ID: 20107672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear magnetic resonance contrast enhancement study of the gastrointestinal tract of rats and a human volunteer using nontoxic oral iron solutions.
    Wesbey GE; Brasch RC; Engelstad BL; Moss AA; Crooks LE; Brito AC
    Radiology; 1983 Oct; 149(1):175-80. PubMed ID: 6611926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging neuroinflammation after stroke: current status of cellular and molecular MRI strategies.
    Deddens LH; Van Tilborg GA; Mulder WJ; De Vries HE; Dijkhuizen RM
    Cerebrovasc Dis; 2012; 33(4):392-402. PubMed ID: 22456323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new method for the aqueous functionalization of superparamagnetic Fe2O3 nanoparticles.
    Herranz F; Morales MP; Roca AG; Vilar R; Ruiz-Cabello J
    Contrast Media Mol Imaging; 2008; 3(6):215-22. PubMed ID: 19072767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Science to Practice: Will Gadolinium Chelates Be Replaced by Iron Chelates in MR Imaging?
    Tweedle MF
    Radiology; 2018 Feb; 286(2):409-411. PubMed ID: 29356647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRI contrast agents: Classification and application (Review).
    Xiao YD; Paudel R; Liu J; Ma C; Zhang ZS; Zhou SK
    Int J Mol Med; 2016 Nov; 38(5):1319-1326. PubMed ID: 27666161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Target-specific superparamagnetic MR contrast agents.
    Weissleder R
    Magn Reson Med; 1991 Dec; 22(2):209-12; discussion 213-5. PubMed ID: 1812348
    [No Abstract]   [Full Text] [Related]  

  • 32. Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging.
    Stoll G; Bendszus M
    Neuroscience; 2009 Feb; 158(3):1151-60. PubMed ID: 18651996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to quantify iron in an aqueous or biological matrix: a technical note.
    Boutry S; Forge D; Burtea C; Mahieu I; Murariu O; Laurent S; Vander Elst L; Muller RN
    Contrast Media Mol Imaging; 2009; 4(6):299-304. PubMed ID: 19998319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Contrast agents in MRT. Substance, effects, pharmacology and validity].
    Reimer P; Vosshenrich R
    Radiologe; 2004 Mar; 44(3):273-83. PubMed ID: 15287365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Speciation of Gd-based MRI contrast agents and potential products of transmetalation with iron ions or parenteral iron supplements.
    Telgmann L; Wehe CA; Künnemeyer J; Bülter AC; Sperling M; Karst U
    Anal Bioanal Chem; 2012 Nov; 404(8):2133-41. PubMed ID: 23001305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomes Loaded with Hydrophobic Iron Oxide Nanoparticles: Suitable T₂ Contrast Agents for MRI.
    Martínez-González R; Estelrich J; Busquets MA
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27472319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasmall water-soluble metal-iron oxide nanoparticles as T1-weighted contrast agents for magnetic resonance imaging.
    Zeng L; Ren W; Zheng J; Cui P; Wu A
    Phys Chem Chem Phys; 2012 Feb; 14(8):2631-6. PubMed ID: 22273844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging.
    Skotland T; Sontum PC; Oulie I
    J Pharm Biomed Anal; 2002 Apr; 28(2):323-9. PubMed ID: 11929675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacological properties of complex iron oxide nanoparticles entering in magnetic resonance tomography contrast agent].
    Akopdzhanov AG; Sergeev AI; Manvelov EV; Semeĭkin AV; Naumenko VIu; Panov VO; Bykov IV; Shimanovskiĭ NL
    Eksp Klin Farmakol; 2010 Jun; 73(6):23-8. PubMed ID: 20726347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iron oxide nanorods as high-performance magnetic resonance imaging contrast agents.
    Mohapatra J; Mitra A; Tyagi H; Bahadur D; Aslam M
    Nanoscale; 2015; 7(20):9174-84. PubMed ID: 25849780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.